GlassScriptPhysician profile
David R Witt
NPI 1538136528
$9,108.70
in general payments reported to CMS, 2019-2025
44 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $800 · 2021: $1,247 · 2022: $1,060 · 2023: $1,573 · 2024: $1,467 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,147.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,156.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $933.11 | 2019-2025 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $830.21 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $736.63 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $734.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $616.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $612.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $485.12 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.33 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $383.72 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $262.09 | 2019-2022 | |
| Amarin Pharma, INC. | $192.39 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $174.69 | 2020-2024 | Ajovy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $131.85 | 2019-2024 | Rexulti |
| Exact Sciences Corporation | $127.46 | 2023-2025 | Cologuard Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.